Ftse Mib
34.683,85
-0,43%
DAX
18.559,25
-0,47%
S&P 500
5.356,20
0,06%
NASDAQ
17.154,26
-0,11%
Bitcoin
70.976,61
0,30%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Denali Therapeutics Inc (DNLI) Denali Therapeutics Inc (DNLI) Notizie

DNLI

Denali Therapeutics (DNLI)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DNLI
DataOraFonteTitoloSimboloCompagnia
06/06/202422:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
05/06/202400:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
03/06/202414:00GlobeNewswire Inc.Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease TherapiesNASDAQ:DNLIDenali Therapeutics Inc
31/05/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
07/05/202422:01GlobeNewswire Inc.Denali Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
01/05/202414:00GlobeNewswire Inc.Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform TrialNASDAQ:DNLIDenali Therapeutics Inc
01/03/202422:51Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:DNLIDenali Therapeutics Inc
27/02/202414:05GlobeNewswire Inc.Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
27/02/202414:00GlobeNewswire Inc.Denali Therapeutics Announces $500 million Private Placement Equity FinancingNASDAQ:DNLIDenali Therapeutics Inc
07/02/202414:00GlobeNewswire Inc.Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™NASDAQ:DNLIDenali Therapeutics Inc
01/02/202414:00GlobeNewswire Inc.Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™NASDAQ:DNLIDenali Therapeutics Inc
08/01/202414:00GlobeNewswire Inc.Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage DiseasesNASDAQ:DNLIDenali Therapeutics Inc
28/11/202301:01PR Newswire (US)Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science LeadersNASDAQ:DNLIDenali Therapeutics Inc
21/11/202312:00PR Newswire (US)Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of GeneticsNASDAQ:DNLIDenali Therapeutics Inc
07/11/202322:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DNLIDenali Therapeutics Inc
07/11/202322:01GlobeNewswire Inc.Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
01/11/202315:30PR Newswire (US)Flagship Pioneering Launches Pioneering IntelligenceNASDAQ:DNLIDenali Therapeutics Inc
11/09/202312:30PR Newswire (US)Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development OfficerNASDAQ:DNLIDenali Therapeutics Inc
30/08/202314:30GlobeNewswire Inc.Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023NASDAQ:DNLIDenali Therapeutics Inc
29/08/202315:00PR Newswire (US)Invaio achieves first registration for citrus greening solution featuring Trecise™ technologyNASDAQ:DNLIDenali Therapeutics Inc
08/08/202322:01GlobeNewswire Inc.Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
21/06/202312:00Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DNLIDenali Therapeutics Inc
21/06/202312:00PR Newswire (US)Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule DrugsNASDAQ:DNLIDenali Therapeutics Inc
20/06/202313:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DNLIDenali Therapeutics Inc
20/06/202313:00GlobeNewswire Inc.Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)NASDAQ:DNLIDenali Therapeutics Inc
16/06/202323:37Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:DNLIDenali Therapeutics Inc
16/05/202312:00PR Newswire (US)Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of BiomimicryNASDAQ:DNLIDenali Therapeutics Inc
08/05/202322:07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:DNLIDenali Therapeutics Inc
08/05/202322:01GlobeNewswire Inc.Denali Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
18/04/202322:08Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:DNLIDenali Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DNLI

La tua Cronologia

BIT
UCG
Unicredit
BIT
STMMI
ST Microelectronics
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
RACE
Ferrari NV
BIT
BPE
Bper Banca
BIT
TRN
Terna Trasmissione Elett...
BIT
LDO
Leonardo
BIT
SRG
Snam
BIT
IVG
Iveco Group NV
BIT
CPR
Davide Campari
BIT
TEN
Tenaris
BIT
A2A
A2A
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network